Horizon, Univ. of Liverpool to Collaborate on Cancer Biomarkers | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery today said that it has inked a research collaboration with the University of Liverpool to use the firm's tools to identify and validate cancer drug targets and biomarkers for personalized cancer therapy and diagnostics.

The partners will utilize Horizon's X-Man cell lines and have access to the firm's panel of over 150 genetically-defined isogenic disease models, said Horizon. The company will work with Michael Clague of the University of Liverpool to identify unique protein biomarker signatures.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.